Loading company…
Oxford biopharmaceutical company developing immunotherapies for chronic viral infections, autoimmune diseases and cancer.
Founded in 2016 and headquartered in Oxford, UK, Vaccitech Limited develops antigen-specific immunotherapeutics, including VTP-200 and VTP-300, which target chronic viral infections, autoimmune diseases and cancer. The company has raised USD 110.50 mn through six funding rounds, with an IPO on April 29, 2021 valuing it at USD 700 mn. In 2023 it reported revenue of USD 819,753.30, earned through partnerships and licensing, and the stage is Series B.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in